First Patient Enrolled in Phase 1 Study of RiMO-301

/ July 13, 2018/ News and Events, RiMO-301

Elk Grove Village, Il.–July 13, 2018– RiMO Therapeutics Inc., a privately held oncology drug development company and a pioneer in Radio-immuno Metal-Organic (RiMO) technology-based cancer immunotherapy, today announced that the first patient has been dosed in a Phase 1 study of RiMO-301 in patients with advanced tumors. RiMO-301 enhances the efficacy of X-ray radiotherapy via the unprecedented radiotherapy-radiodynamic therapy (RT-RDT) mode of action. “Initiation of this study represents not only a significant milestone for RiMO Therapeutics but also the field of nanoscale metal-organic frameworks (nMOFs), as RiMO-301 is the first nMOF-based product to enter clinical trials.” said Wenbin Lin, Ph.D., founder and chairman of RiMO and also the James Franck Professor of Chemistry, Radiation & Cellular Oncology, and the Ludwig Center for Metastasis Research at

Read More

Chemical and Engineering News Feature

/ March 29, 2018/ News and Events

Chemical and Engineering News featured the proprietary RiMO technology for its ability to generate two types of tumor-fighting reactive oxygen species with deeply penetrating X-rays and to activate T cells to attack tumor tissue systemically.

UChicago News Feature

/ March 29, 2018/ News and Events

Proprietary RiMO technology was featured in UChicago News for its ability to significantly reduce X-ray doses used in radiotherapy and enhance checkpoint blockade immunotherapy.

RiMO Therapeutics Closes Seed Round Investment

/ February 15, 2017/ News and Events

RiMO Therapeutics Inc., an oncology company commercializing the Radio-immuno Metal-Organic (RiMO) technology for radiotherapy and immunotherapy of solid tumors, has closed SEED round investment. The SEED investors share Dr. Wenbin Lin’s passion for developing disruptive technologies to combat the most difficult to treat cancers. The SEED round funds will be used to carry out clinical trials on RiMO-301, the first clinical candidate for radiotherapy and radio-immunotherapy of recurrent and metastatic head and neck cancer. “I am grateful to Seed investors for their strong support and for their faith in our revolutionary technologies for cancer therapy,” said Dr. Wenbin Lin, Founder and Chairman of RiMO Therapeutics. “I look forward to steering the RiMO technology through early phase clinical trials.”